Related Experiment Video

Updated: Jul 27, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Antimutagenesis/anticarcinogenesis 2001: screening, methods and biomarkers

P H Lohman1, J M Gentile, G Gentile

  • 1Department of Radiation Genetics and Chemical Mutagenesis, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL, Leiden, The Netherlands.

Mutation Research
|September 12, 2001
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Experiment Videos

Last Updated: Jul 27, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Articles linked to this work by shared authors, journal, and citation graph.

The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.

Critical reviews in oncology/hematology·2026

20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

ESMO open·2025

Effective and safe use of alirocumab in spinal and bulbar muscular atrophy with high cardiovascular risk: a case report.

European review for medical and pharmacological sciences·2025

Care pathway of asylum seekers in the health care access points following inclusion in the PREMENTADA project: an observational study.

Public health·2024

Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis.

ESMO open·2023

Mothers against decapentaplegic homolog 3-activated FAT atypical cadherin 2 regulates programmed death ligand-1 to mediate immune evasion in lung squamous cell carcinoma.

Mutation research·2026

Potential targets and molecular mechanisms of curcumin in treating Laryngeal and Pharyngeal Carcinoma throat cancer based on network pharmacology and bioinformatics analysis.

Mutation research·2026

Non-clonal interphase markers of chromosomal instability in malignancy acquisition and cancer progression.

Mutation research·2026

miR-145-5p induces ferroptosis by targeting Notch2 to suppress melanoma progression.

Mutation research·2026

Monoallelic germline RAD51C, RAD51D, and BRIP1 variants in hereditary cancer testing: Variant spectrum and clinical counselling implications.

Mutation research·2026

Prediction of hepatocellular carcinoma associated biomarkers in TP53 gene; A comprehensive in silico analysis.

Mutation research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us